Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Non-Hodgkin's Lymphoma

Autologous stem cell transplantation (ASCT) with immunologically purged progenitor cells in patients with advanced stage follicular lymphoma after early partial or complete remission: toxicity, follow-up of minimal residual disease and survival

Bone Marrow Transplantation volume 26, pages 1051–1056 (2000)Cite this article

Abstract

The role of autologous stem cell transplant (ASCT) in indolent lymphomas is a controversial issue. From 1994 to 1999, we performed ASCT with immunologically purged progenitor cells in 15 patients with advanced stage follicular lymphoma (FL) after early partial or complete remission. Results of the purging strategy and follow-up of minimal residual disease after transplant were analyzed with PCR amplification of bcl-2/IgH rearrangement for the t(14;18) translocation. A comparison of transplanted patients with a group of controls was carried out to evaluate differences in progression-free survival and overall survival. Eighty percent of patients received one chemotherapy regimen before ASCT and were in first remission. All the patients received cyclophosphamide plus hyperfractionated total body irradiation as the conditioning regimen. Nine patients were transplanted with bone marrow (BM) and six with peripheral blood progenitor cells (PBPC). Engraftment was delayed in one patient transplanted with BM. Two patients died during the transplant procedure. Ten of 12 evaluable patients were PCR positive in the BM for bcl-2 rearrangement at diagnosis. Six of them (60%) were still positive after chemotherapy, and one patient was transplanted with a positive hematopoietic product after purging. With a median follow-up of 27 months, six of eight evaluable patients still remain PCR negative in the BM. With a median follow-up of 4.7 years from diagnosis, progression-free survival was 83% (95% CI: 63–100). The risk of disease progression of non-transplanted patients was 19.2 times higher than that of transplanted patients (P = 0.01), but no differences were found in overall survival. Regarding patients in first remission, the risk of relapse was 12.6 times higher in non-transplanted than in transplanted patients (P = 0.04). This procedure seems to offer a good chance to achieve a PCR-negative state and prolonged freedom from recurrence. According to these results, prospective randomized trials are warranted. Bone Marrow Transplantation (2000) 26, 1051–1056.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Salar A, Fernández de Sevilla A, Romagosa V et al. Distribution and incidence rates of lymphoid neoplasms according to the REAL classification in a single institution. A prospective study of 940 cases Eur J Haematol 1997 59: 231–237

    Article  CAS  Google Scholar 

  2. Young RC, Longo DL, Glatstein E et al. The treatment of indolent lymphomas: watchful waiting compared with aggressive combined modality treatment Semin Hematol 1988 25: 11–16

    CAS  PubMed  Google Scholar 

  3. Horning SJ, Rosenberg SA . The natural history of initially untreated low-grade non-Hodgkin's lymphoma New Engl J Med 1984 311: 1471–1475

    Article  CAS  Google Scholar 

  4. Price CGA, Rohatiner AZS, Steward W et al. Interferon alfa-2b in addition to chlorambucil in the treatment of follicular lymphoma: preliminary results of a randomized trial in progress Eur J Cancer 1991 27: S34–S36

    Article  Google Scholar 

  5. Arranz R, García-Alfonso P, Sobrini P et al. Role of interferon alfa 2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization J Clin Oncol 1998 16: 1538–1546

    Article  CAS  Google Scholar 

  6. Solal-Cèligny P, Lepage E, Brousse N et al. A doxorubicin-containing regimen with or without interferon alpha-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the GELF 86 trial J Clin Oncol 1998 16: 2332–2338

    Article  Google Scholar 

  7. Redman JR, Cabanillas F, Velasquez WS et al. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma J Clin Oncol 1992 10: 790–794

    Article  CAS  Google Scholar 

  8. Solal-Cèligny P, Brice P, Brousse N et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte J Clin Oncol 1996 14: 514–519

    Article  Google Scholar 

  9. McLaughlin P, Hagemeister FB, Romaguera JE et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma trial J Clin Oncol 1996 14: 1262–1268

    Article  CAS  Google Scholar 

  10. Hochster H, Oken M, Winter J et al. Prolonged time to progression (TTP) in patients with low-grade lymphoma (LGL) treated with cyclophosphamide (C) and fludarabine (F) Proc ASCO 1998 17: 17a (Abstr. 66)

    Google Scholar 

  11. Maloney DG, Grillo-López AJ, White CA et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low grade non-Hodgkin's lymphoma Blood 1997 90: 2188–2195

    CAS  PubMed  Google Scholar 

  12. McLaughlin P, Grillo-López AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program J Clin Oncol 1998 16: 2825–2833

    Article  CAS  Google Scholar 

  13. Czuczman MS, Grillo-López AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy J Clin Oncol 1999 17: 268–276

    Article  CAS  Google Scholar 

  14. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non-Hodgkin's lymphoma New Engl J Med 1995 333: 1540–1545

    Article  CAS  Google Scholar 

  15. Schouten HC, Bierman PJ, Vaughan WP et al. Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation Blood 1989 74: 2579–2584

    CAS  PubMed  Google Scholar 

  16. Brenner M, Rill D, Moen R et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation Lancet 1993 341: 85–86

    Article  CAS  Google Scholar 

  17. Cleary ML, Smith SD, Sklar J . Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2 immunoglobulin transcript resulting from the t(14;18) translocation Cell 1986 47: 19–28

    Article  CAS  Google Scholar 

  18. Martín-Henao GA, Picón M, Limón A et al. Immunomagnetic bone marrow (BM) and peripheral blood progenitor cell (PBPC) purging in follicular lymphoma (FL) Bone Marrow Transplant 1999 23: 579–587

    Article  Google Scholar 

  19. Sambrook J, Fritsch EF, Maniatis T . Molecular Cloning: a Laboratory Manual Cold Spring Harbor Laboratory: Cold Spring Harbor, NY 1989

    Google Scholar 

  20. Gribben JG, Freedman AS, Woo SD et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable bcl-2 translocation have residual cells containing the bcl-2 rearrangement at evaluation and following treatment Blood 1991 78: 3275–3280

    CAS  PubMed  Google Scholar 

  21. Gribben JG, Freedman AS, Neuberg D et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma New Engl J Med 1991 325: 1525–1533

    Article  CAS  Google Scholar 

  22. Gribben JG, Neuberg D, Freedman AS et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma Blood 1993 81: 3449–3457

    CAS  PubMed  Google Scholar 

  23. Freedman AS, Gribben JG, Neuberg D et al. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission Blood 1996 88: 2780–2786

    CAS  PubMed  Google Scholar 

  24. Zwicky CS, Maddocks AB, Andersen N, Gribben JG . Eradication of polymerase chain reaction detectable immunoglobulin gene rearrangement in non-Hodgkin's lymphoma is associated with decreased relapse after autologous bone marrow transplantation Blood 1996 88: 3314–3322

    CAS  PubMed  Google Scholar 

  25. Lopez-Guillermo A, Cabanillas F, McLaughlin P et al. The clinical significance of molecular response in indolent follicular lymphomas Blood 1998 91: 2955–2960

    CAS  PubMed  Google Scholar 

  26. Bierman P, Vose J, Anderson J et al. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma J Clin Oncol 1997 15: 445–450

    Article  CAS  Google Scholar 

  27. Bastion Y, Brice P, Haioun C et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor prognosis follicular lymphoma Blood 1995 86: 3257–3262

    CAS  PubMed  Google Scholar 

  28. Rohatiner A, Johnson P, Price C et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma J Clin Oncol 1994 12: 1177–1184

    Article  CAS  Google Scholar 

  29. Hass R, Moos M, Múhle R et al. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma Bone Marrow Transplant 1996 17: 149–155

    Google Scholar 

  30. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation J Clin Oncol 1988 6: 1562–1568

    Article  CAS  Google Scholar 

  31. Stone RM, Neuberg D, Soiffer R et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma J Clin Oncol 1994 12: 2535–2542

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Hematology, Hospital Duran i Reynals, Institut Catalá d'Oncologìa, Barcelona, Spain

    E González-Barca, A Fernández de Sevilla, J Petit & A Grañena

  2. Department of Cytology and Pathology, Ciudad Sanitaria y Universitaria de Bellvitge, Barcelona, Spain

    A Domingo-Claros & V Romagosa

  3. Department of Cryobiology and Cell Therapy, Cancer Research Institute, Barcelona, Spain

    GA Martín-Henao, M Carmona & J García

  4. Department of Epidemiology, Hospital Duran i Reynals, Institut Catalá d'Oncologìa, Barcelona, Spain

    S De Sanjose

Authors
  1. E González-Barca
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Fernández de Sevilla
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Domingo-Claros
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V Romagosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. GA Martín-Henao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S De Sanjose
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Carmona
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J Petit
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J García
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A Grañena
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

González-Barca, E., Fernández de Sevilla, A., Domingo-Claros, A. et al. Autologous stem cell transplantation (ASCT) with immunologically purged progenitor cells in patients with advanced stage follicular lymphoma after early partial or complete remission: toxicity, follow-up of minimal residual disease and survival. Bone Marrow Transplant 26, 1051–1056 (2000). https://doi.org/10.1038/sj.bmt.1702660

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702660

Keywords

This article is cited by

Search

Advanced search

Quick links